Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MEDP
stocks logo

MEDP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
689.40M
+28.48%
4.182
+13.96%
679.00M
+21.56%
3.758
+2.39%
690.52M
+14.45%
4.076
+31.48%
Estimates Revision
The market is revising Upward the revenue expectations for Medpace Holdings, Inc. (MEDP) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by 12.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.24%
In Past 3 Month
Stock Price
Go Up
up Image
+12.94%
In Past 3 Month
Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
7 Hold
2 Sell
Hold
Current: 544.770
sliders
Low
425.00
Averages
524.89
High
655.00
Current: 544.770
sliders
Low
425.00
Averages
524.89
High
655.00
BMO Capital
Market Perform
initiated
$600
2025-11-12
Reason
BMO Capital
Price Target
$600
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Medpace with a Market Perform rating and $600 price target. The firm views the stock's valuation as full in a "tepid" biotech funding backdrop. The shares at current levels leave "little cushion for additional potential macro volatility," the analyst tells investors in a research note.
Truist
Jailendra Singh
Hold
maintain
$436 -> $555
2025-10-27
Reason
Truist
Jailendra Singh
Price Target
$436 -> $555
2025-10-27
maintain
Hold
Reason
Truist analyst Jailendra Singh raised the firm's price target on Medpace to $555 from $436 and keeps a Hold rating on the shares after meeting with its management team to discuss Q3 results, book-to-bill targets, and expectations for 2026. The firm's higher assumed forward earnings multiple at 20-tims vs. 18-times prior reflects its increased confidence in the continuing recovery in the Biotech market, the analyst tells investors in a research note.
Baird
Neutral
maintain
$491 -> $613
2025-10-24
Reason
Baird
Price Target
$491 -> $613
2025-10-24
maintain
Neutral
Reason
Baird raised the firm's price target on Medpace to $613 from $491 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
TD Cowen
Sell
maintain
$356 -> $462
2025-10-24
Reason
TD Cowen
Price Target
$356 -> $462
2025-10-24
maintain
Sell
Reason
TD Cowen raised the firm's price target on Medpace to $462 from $356 and keeps a Sell rating on the shares. The firm saidthe company's preliminary 2026 outlook as well as cancels being "well-behaved" and pre-backlog pipeline value growth of 30% year-over-year is a positive sign for the company's fundamental outlook.
Barclays
Luke Sergott
Underweight
maintain
$425 -> $485
2025-10-24
Reason
Barclays
Luke Sergott
Price Target
$425 -> $485
2025-10-24
maintain
Underweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Medpace to $485 from $425 and keeps an Underweight rating on the shares following the earnings report. The firm says it was "overly bearish" on Medpace's demand environment.
Mizuho
Outperform
maintain
$575 -> $655
2025-10-24
Reason
Mizuho
Price Target
$575 -> $655
2025-10-24
maintain
Outperform
Reason
Mizuho raised the firm's price target on Medpace to $655 from $575 and keeps an Outperform rating on the shares post the Q3 report. The firm sees additional estimate upside for Medpace, saying it is not assuming a full industry recovery or additional share repurchases.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Medpace Holdings Inc (MEDP.O) is 35.08, compared to its 5-year average forward P/E of 30.12. For a more detailed relative valuation and DCF analysis to assess Medpace Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
30.12
Current PE
35.08
Overvalued PE
35.62
Undervalued PE
24.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.44
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
26.29
Undervalued EV/EBITDA
18.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.49
Current PS
0.00
Overvalued PS
5.32
Undervalued PS
3.66
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MEDP News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-10-22 (ET)
2025-10-22
16:23:45
Medpace increases FY25 EPS forecast to $14.60-$14.86, up from $13.76-$14.53
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03NASDAQ.COM
GEHC Launches Allia Moveo to Enhance Mobility in Interventional Care

  • Introduction of Allia Moveo: GE HealthCare has launched Allia Moveo, a next-generation interventional imaging platform designed to enhance mobility, access, and workflow in medical procedures, featuring a compact, cable-free C-arm for improved patient comfort and high-quality imaging.

  • Technological Advancements: The platform integrates AI-driven workflow tools and multi-modality capabilities, aiming to streamline clinician operations and support higher case volumes in minimally invasive procedures, thereby enhancing GEHC's competitiveness in the market.

  • Market Performance: Following the announcement, GEHC's shares remained stable, with a year-to-date gain of 1.3%, contrasting with a 4.9% decline in the industry, while the S&P 500 has increased by 18.8%.

  • Future Prospects: Allia Moveo is expected to strengthen GEHC's position in interventional imaging, drive adoption across diverse care settings, and generate recurring revenue through service and software integrations, with FDA clearance pending.

[object Object]
Preview
4.5
11-29Benzinga
Wall Street Anticipates Fifth Consecutive Day of Gains as Silver Reaches Record High of $55: Market Movers for Friday

  • Market Performance: Stocks are on track for a fifth consecutive day of gains, with the S&P 500 up 0.4% and nearing its all-time high, driven by increased risk appetite and expectations of a Federal Reserve interest rate cut.

  • Tech and Crypto Gains: Intel Corp. led the S&P 500 with an 8% increase, while crypto-related stocks surged following Bitcoin's stabilization near $90,000, with Circle Internet Group rising 10%.

  • Metals Market Rally: Silver prices soared nearly 5% to an all-time high, driven by low Chinese inventories, while gold and copper also saw significant gains, reflecting strong demand and supply issues.

  • Energy Commodities Rise: Natural gas prices hit a three-year high with a 4.5% increase, and crude oil prices rose 1.5%, as market optimism regarding geopolitical tensions adjusted expectations.

[object Object]
Preview
4.5
11-25Yahoo Finance
Dow Jones Futures: Strategies as Stock Market Reaches Crucial Milestone; Tesla, Palantir, and Broadcom Surge

  • Market Movement: The stock market has reached a significant level, indicating potential changes ahead.

  • Stock Performance: Companies like Tesla, Palantir, and Broadcom saw notable increases in their stock prices.

  • Buy Signal: Among the mentioned stocks, only one has shown a clear buy signal for investors.

  • Investor Caution: Despite the market's rise, uncertainty remains regarding its sustainability and future direction.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Medpace Holdings Inc (MEDP) stock price today?

The current price of MEDP is 544.77 USD — it has decreased -5.5 % in the last trading day.

arrow icon

What is Medpace Holdings Inc (MEDP)'s business?

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

arrow icon

What is the price predicton of MEDP Stock?

Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Medpace Holdings Inc (MEDP)'s revenue for the last quarter?

Medpace Holdings Inc revenue for the last quarter amounts to 659.90M USD, increased 23.74 % YoY.

arrow icon

What is Medpace Holdings Inc (MEDP)'s earnings per share (EPS) for the last quarter?

Medpace Holdings Inc. EPS for the last quarter amounts to 3.86 USD, increased 28.24 % YoY.

arrow icon

What changes have occurred in the market's expectations for Medpace Holdings Inc (MEDP)'s fundamentals?

The market is revising Upward the revenue expectations for Medpace Holdings, Inc. (MEDP) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by 12.94%.
arrow icon

How many employees does Medpace Holdings Inc (MEDP). have?

Medpace Holdings Inc (MEDP) has 5900 emplpoyees as of December 05 2025.

arrow icon

What is Medpace Holdings Inc (MEDP) market cap?

Today MEDP has the market capitalization of 15.35B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free